Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021495 | 1.00 | HTT (0.44) | HTTPOLBLMNAGAAMAPT | |
| SCHEMBL11068617 | 0.95 | HTT (0.48) | HTTPOLBLMNAGAAMAPT | |
| SCHEMBL31357139 | 0.91 | CES2 (0.46) | HTTPOLBLMNAGAAMAPT | |
| SCHEMBL27006326 | 0.88 | KMT2A (0.54) | HTTPOLBGAAMAPTMEN1 | |
| SCHEMBL3500438 | 0.83 | TNK2 (0.44) | POLBLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1025068 | 0.83 | SLC6A2 (0.52) | POLBLMNA | |
| SCHEMBL2367956 | 0.81 | MEN1 (0.56) | HTTMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5206947 | 0.78 | IDO1 (0.46) | HTTPOLBLMNAGAAMAPT | |
| SCHEMBL8740885 | 0.78 | PKM (0.44) | HTTLMNAGAAMEN1KMT2A | |
| SCHEMBL10924129 | 0.78 | MAPK1 (0.41) | LMNAMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0384134-A2 | Preparation of linear polycarbonates from cyclic oligomer compositions using aryl tetrahydropyranyl ether catalyst | GENERAL ELECTRIC COMPANY (US) | 1990-08-29 | — | — | EP | claimed |
| US-4927910-A | Preparation of linear polycarbonates from cyclic oligomer compositions using aryl tetrahydropyranyl ether catalyst | GENERAL ELECTRIC COMPANY (US) | 1990-05-22 | — | — | US | claimed |
| JP-2283725-A | — | — | None | — | — | JP | disclosed |
| US-8362150-B2 | Gas-phase anionic polymerization | BRIDGESTONE CORPORATION (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20090209708-A1 | GAS-PHASE ANIONIC POLYMERIZATION | BRIDGESTONE CORPORATION (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090143332-A1 | Cyclodextrin Cyanohydrins | AARHUS UNIVERSITET (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2006084469-A1 | CYCLODEXTRIN CYANOHYDRINS | AARHUS UNIVERSITET (DK) | 2006-08-17 | — | — | WO | disclosed |
| JP-H02283725-A | PRODUCTION OF LINEAR POLYCARBONATE FROM CYCLIC OLIGOMER COMPOSITION BY USING ARYL TETRAHYDROPYRANYL ETHER | GENERAL ELECTRIC CO <GE> | 1990-11-21 | — | — | JP | disclosed |
| EP-0384134-A2 | Preparation of linear polycarbonates from cyclic oligomer compositions using aryl tetrahydropyranyl ether catalyst | GENERAL ELECTRIC COMPANY (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4297129-A | HERBICIDES; WILD OATS; NONPHYTOTOXIC | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143332-A1 | Cyclodextrin Cyanohydrins | PYGL, CBR3, CYP2B6 | HTT 1324/4885POLB 4038/4885LMNA 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.